Astec LifeSciences Limited — Important, 08-07-2026: Updates

Astec LifeSciences reports robust operational recovery in the recent fiscal year, achieving EBITDA break-even and narrowing loss to ₹80.88 Cr on ₹453.22 Cr revenue. Strategic CDMO business surged 2.5x in H2, supported by new facilities. A Rights Issue raised ₹249.35 Cr. New leadership includes a Chairperson and Executive Director. Labour Code changes impacted financials.